WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
I was 'brokefished' by my friend for £400
Chris Pratt relies on 'wisdom' of father
Candice Swanepoel stuns in a form
General Hospital's Brook Lynn and Chase tie the knot on Thursday in the second episode of a three
I had a £100 shampoo lesson with Kate Hudson's hairdresser
College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at
Dua Lipa, Harry Styles and Ed Sheeran are named among Britain's richest under 40s
Philippines blames China for loss of giant clams in disputed shoal and urges environmental inquiry
Vinnie Jones 'to discuss new romance' with Emma Ford in second series of In The Country